Monteloeder vows to help customers

Monteloeder promises to invest €600,000 in helping its customers launch new products containing MetabolAid, if it wins a €2 million grant from the EU’s Horizon 2020 innovation programme.

It has already secured €50,000 after MetabolAid, which addresses the symptoms of metabolic syndrome, was ranked top in the first stage of the programme. It is now finalising its application for stage 2 funding.

If successful, Monteloeder will match fund the cost of developing, commercialising and marketing consumer products containing MetabolAid in Europe, the USA and Asia – up to a maximum of €200,000 in each region.

It has already identified a partner in Japan for the Asian market, but continues to seek two companies to work with elsewhere. The money will also pay for an application to obtain EFSA approval for MetabolAid under the EU’s Nutrition & Health Claims Regulation.

Fernando Cartagena, global head of marketing at Monteloeder, says, “Launching a new product to consumers can be risky and expensive, so this represents an excellent opportunity for us to help our customers by taking on some of the financial burden.

“The Horizon 2020 programme rewards companies who take a collaborative approach to innovation and the commercialisation of science, so we are confident our commitment to match fund new product development with our three selected partners will resonate with the expert panel that evaluates our application.

“Very few companies are successful in winning grants, and the fact that MetabolAid did so well in the first stage of the process gives us great hope for this next stage.”

Related content

Leave a reply

Food and Drink Technology